MDxHealth SA

MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. It operates through the following geographical segments: United States of America, The Netherlands, Belgium, Spain, Poland, Italy, Rest of EU, and Rest of the World. The firm offers ConfirmMDx, SelectMDx, AssureMDx, InformMDx, SelectMDx, and MonitorMDx. The company was founded by Herman Spolders and Philip S. Devine on January 10, 2003 and is headquartered in Herstal, Belgium.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MDxHealth reports strong Q2 revenue growth and operational improvements

MDxHealth's Q2 2024 performance reflects robust revenue growth, driven by increased test volumes and improved margins.
The company's strategic focus on revenue drivers and operational efficiency has led to a reduction in operating losses.
While facing challenges in a competitive market, MDxHealth is well-positioned to capitalize on growth opportunities and deliver strong results.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. It operates through the following geographical segments: United States of America, Europe and Rest of the World. The firm offers ConfirmMDx, SelectMDx, AssureMDx, InformMDx, SelectMDx, and MonitorMDx. The company was founded by Herman Spolders and Philip S. Devine on January 10, 2003 and is headquartered in Herstal, Belgium.

NEWS RELEASE - REGULATED INFORMATION 8 MARCH 202 3 , 4 : 0 0 PM EST / 22:00 CET

MDxHealth Reports Financial Year 2022 Results and Provides Business Update and Outlook for 2023

MDxHealth Announces Exercise of Option

IRVINE, CA, and HERSTAL, BELGIUM – March 3, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, announces today in accordance with Article 14 of the Belgian Act of 2 May 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act"), that it received the following notifications.

MDxHealth Shareholder Transparency Declarations

IRVINE, CA, and HERSTAL, BELGIUM – February 28, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH), a commercial-stage precision diagnostics company, today announced that Michael McGarrity, chief executive officer, will present at Cowen's 43rd Annual Health Care Conference on Monday, March 6th, 2023 at 1:30pm ET. A live webcast of the presentation will be available on the Company's website.

MDxHealth to Participate in 43rd Annual Cowen Healthcare Conference

MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2022, after market close on Wednesday, March 8, 2023.

MDxHealth to Present Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023

MDxHealth (NASDAQ: MDXH ) stock is falling on Friday after the healthcare company revealed plans for a proposed public stock offering. With this offering, MDxHealth is seeking to sell $40 million of its American Depositary Shares (ADSs) through the Nasdaq Capital Market.

Why Is MDxHealth (MDXH) Stock Down 40% Today?

IRVINE, CA, and HERSTAL, BELGIUM – February 3, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering of 10,000,000 American Depositary Shares (“ADSs”) (each representing 10 ordinary shares of the Company without nominal value) (the “Offering”) at a price to the public of USD 4.00 per ADS1 for total gross proceeds of USD 40.0 million2 before deducting commissions and estimated offering expenses. In connection with the Offering, mdxhealth has granted the underwriters a 30-day option to purchase 1,500,000 additional ADSs, on the same terms and conditions.

MDxHealth Announces Pricing of Offering of ADSs in the United States

NEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION FEBRUARY 1, 2023, 4PM ET/ 22:00 CET

MDxHealth Announces Launch of Offering of ADSs in the United States

NEWS RELEASE – REGULATED INF O RMATION 20 JANUARY 202 3 , 1 : 0 0 a m ET / 7 : 0 0 am CET

MDxHealth Provides Updated and Supplemental Financial Information Related to Acquisition of GPS Test

NEWS RELEASE – INSIDE AND REGULATED INF O RMATION 9 JANUARY 202 3 , 4 PM ET / 22 :00 CET

MDxHealth Reports Preliminary 2022 Revenues and Reaffirms 2023 Revenue Guidance

NEWS RELEASE – REGULATED INFORMATION December 19, 2022 , 5:00PM EDT / 23:00 CET

Mdxhealth files U.S. Shelf Registration on Form F-3

NEWS RELEASE – INSIDE AND REGULATED INFORMATION 29 NOVEM BER 2022, 4:00PM EDT / 22:00 CET

MDxHealth Provides Business Update

NEWS RELEASE - REGULATED INFORMATION 27 OCTOBER 202 2 , 4:00PM EDT / 22:00 CET

MDxHealth Reports Q3-2022 Results

NEWS RELEASE - REGULATED INFORMATION25 AUGUST 2022, 4:00PM EDT, 22:00 CET

MDxHealth Reports Half Year 2022 Results

MDxHealth (MDXH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for MDxHealth (MDXH) This Earnings Season?

NEWS RELEASE - REGULATED INFORMATION                 25 May 2022 , 4:00 p.m. EDT / 22:00 CET

MDxHealth Announces Results of its Annual and Extraordinary General Shareholders' Meetings and Resignation of Director

NEWS RELEASE - REGULATED INFORMATION 27 APRIL 202 2 , 4:00PM EDT / 22:00 CET

MDxHealth Reports Q1-2022 Results

NEWS RELEASE March 30, 2022, 4: 3 0 PM EST / 22: 3 0 CET

MDxHealth to Participate in the 14th Annual Kempen Life Sciences Conference

MDxHealth SA (MXDHF) CEO Michael McGarrity on Q4 2021 Results - Earnings Call Transcript

NEWS RELEASE - REGULATED INFORMATION 2 MARCH 202 2 , 4 : 0 0 PM EST / 22:00 CET

MDxHealth Reports Financial Year 2021 Results and Provides Outlook and Guidance for 2022

NEWS RELEASE 17 February 2022, 4:00 PM EST / 22:00 CET

MDxHealth to Present Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 2nd

NEWS RELEASE 9 FEBRUARY 2022, 4:00 PM EST / 22:00 CET

MDxHealth to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

NEWS RELEASE – REGULATED INFORMATION         15 November 2021 , 11:00 p .m. CET

MDxHealth Announces Completion of Initial Public Offering of ADSs in the United States

NEWS RELEASE - REGULATED INFORMATION INSIDE INFORMATION 4 NOVEMBER 2021, 13:00 CET

MDxHealth Announces Pricing of Initial Public Offering of ADSs in the United States

MDxHealth has filed to raise $50.5 million in a U.S. IPO.

News for MDxHealth SA Stock (MDXH)